[1]洪娟,陈运凡,沈俊杰,等.靶向前列腺干细胞抗原的嵌合抗原受体T细胞构建及其抗肿瘤作用[J].第三军医大学学报,2018,40(12):1053-1059.
 HONG Juan,CHEN Yunfan,SHEN Junjie,et al.Construction of T cells expressing chimeric antigen receptor targeting prostate stem cell antigen and its anti-tumor effect in tumor-bearing mice[J].J Third Mil Med Univ,2018,40(12):1053-1059.
点击复制

靶向前列腺干细胞抗原的嵌合抗原受体T细胞构建及其抗肿瘤作用(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
40卷
期数:
2018年第12期
页码:
1053-1059
栏目:
临床医学
出版日期:
2018-06-30

文章信息/Info

Title:
Construction of T cells expressing chimeric antigen receptor targeting prostate stem cell antigen and its anti-tumor effect in tumor-bearing mice
作者:
洪娟陈运凡沈俊杰徐艳敏钱程  
陆军军医大学(第三军医大学)第一附属医院生物治疗中心
Author(s):
HONG Juan CHEN Yunfan SHEN Junjie XU Yanmin QIAN Cheng

Biological Therapy Center, First Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400038, China

关键词:
嵌合抗原受体前列腺干细胞抗原肿瘤免疫治疗慢病毒
Keywords:
chimeric antigen receptor prostate stem cell antigen tumor immunotherapy lentivirus
分类号:
R322.64;R392-33;R73-362
文献标志码:
A
摘要:

目的     制备表达靶向前列腺干细胞抗原(prostate stem cell antigen,PSCA)的嵌合抗原受体修饰的T细胞(chimeric antigen receptor T-cell,CAR-T),研究其嵌合抗原受体(chimeric antigen receptor,CAR)的表达及其对肿瘤细胞的体内外杀伤作用。方法基因合成靶向PSCA的单克隆抗体的轻链和重链可变区(PSCA ScFv),利用酶切将其插入慢病毒载体中。病毒感染T淋巴细胞后,通过流式细胞术检测PSCA-CAR在T淋巴细胞中表达的阳性率。利用体外杀伤实验及ELISA实验分别检测PSCA-CAR-T细胞对PSCA阳性的HeLa细胞及PSCA阴性的T24细胞的杀伤效果、特异性及其细胞因子分泌情况。利用NOG小鼠背部皮下注射HeLa细胞建立移植瘤模型。结果酶切结果表明慢病毒载体 pL-PSCA-G4H-28TM-28BBζ构建成功,DNA测序结果表明PSCACAR的载体序列正确;病毒感染T淋巴细胞后CAR表达阳性率为53.9%;获得的PSCA-CAR-T细胞不管是在高效靶比短时作用条件下还是低效靶比长时作用条件下,其对PSCA阳性肿瘤细胞的杀伤作用均明显强于PSCA阴性肿瘤细胞(P<0.01);同时获得的PSCA-CAR-T在受到PSCA阳性肿瘤细胞刺激时,分泌的细胞因子量显著高于对照的T细胞(P<0.01),而在受到PSCA阴性肿瘤细胞刺激时几乎不分泌细胞因子。体内实验证实PSCA-CART细胞在体内有显著的肿瘤抑制效果(P<0.01)。结论成功制备了靶向PSCA的CAR-T细胞,该CAR-T细胞能特异杀伤PSCA阳性的肿瘤细胞。
 

Abstract:

ObjectiveTo construct genetically modified T cells expressing chimeric antigen receptor (CAR) targeting prostate stem cell antigen (PSCA) and test the cytotoxicity of these cells against tumor cells both in vitro and in a tumorbearing mouse model. MethodsThe sequences encoding the light and heavy chain variable regions of a monoclonal antibody targeting PSCA were synthesized and integrated into lentiviral vectors using restriction enzymes. Human T lymphocytes isolated from peripheral blood mononuclear cells were infected with the recombinant lentivirus and the positivity rate of PSCACAR expression in the T lymphocytes was detected using flow cytometry. Cytotoxic assay was performed to evaluate the specific cytotoxicity of the genetically modified T cells against the PSCApositive HeLa cells and PSCAnegotive T24 cells, and ELISA was used to detect cytokine secretion by the cells. The antitumor effect of PSCACART cells was also tested in a NOG mouse model bearing HeLa cell xenograft. ResultsDNA sequencing analysis suggested correct synthesis of PSCACAR sequences, and enzyme digestion verified successful construction of the lentiviral vector PLPSCAG4H28TM28BBζ. The positivity rate of CAR expression was 53.9% in the T lymphocytes after infection with the lentiviral vector. The PSCACART cells showed a significantly stronger cytotoxicity against PSCApositive tumor cells than against PSCAnegative tumor cells (P<001) both in shortterm coincubation at a high effectivetarget ratio and in longterm coincubation at a low effectivetarget ratio. The PSCACART cells secreted significantly higher levels of cytokines than the control T cells upon stimulation by PSCApositive tumor cells (P<001), but the secretions were almost undetectable upon stimulation by PSCAnegative tumor cells. In the in vivo experiment, PSCACART cells exhibited a significant tumorsuppressive effect in the tumorbearing mice (P<001). ConclusionPSCACART cells capable of specific killing of PSCApositive tumor cells are successfully constructed both in vitro and in vivo.

参考文献/References:


[1]KOWOLIK C M, TOPP M S, GONZALEZ S, et al. CD28 costimulation provided through a CD19specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells[J]. Cancer Res, 2006,66(22): 10995-11004. DOI: 10.1158/00085472.CAN060160.
[2]SADELAIN M, BRENTJENS R, RIVIRE I. The basic principles of chimeric antigen receptor design[J]. Cancer Discov, 2013,3(4): 388-398. DOI: 10.1158/21598290.CD 120548.
[3]REITER R E, GU Z, WATABE T, et al. Prostate stem cell antigen:  a cell surface marker overexpressed in prostate cancer[J]. Proc Natl Acad Sci U S A, 1998, 95(4): 1735-1740.
[4]YANG X, GUO Z, LIU Y, et al. Prostate stem cell antigen and cancer risk, mechanisms and therapeutic implications[J]. Expert Rev Anticancer Ther, 2014, 14(1): 31-37. DOI:  10.1586/14737140.2014.845372.
[5]Study Group of Millennium Genome Project for Cancer, SAKAMOTO H, YOSHIMURA K, et al. Genetic variation in PSCA is associated with susceptibility to diffusetype gastric cancer[J]. Nat Genet, 2008, 40(6): 730-740. DOI:  10.1038/ng.152.
[6]LOCHHEAD P, FRANK B, HOLD G L, et al. Genetic variation in the prostate stem cell antigen gene and upper gastrointestinal cancer in white individuals[J]. Gastroenterology, 2011, 140(2): 435-441. DOI:  10.1053/j.gastro.2010.11.001.
[7]LU Y, CHEN J, DING Y, et al. Genetic variation of PSCA gene is associated with the risk of both diffuse and intestinaltype gastric cancer in a Chinese population[J]. Int J Cancer, 2010, 127(9): 2183-2189. DOI: 10.1002/ijc.25228.
[8]MATSUO K, TAJIMA K, SUZUKI T, et al. Association of prostate stem cell antigen gene polymorphisms with the risk of stomach cancer in Japanese[J]. Int J Cancer, 2009, 125(8): 1961-1964. DOI:  10.1002/ijc.24519.
[9]GRUBBS E G, ABDELWAHAB Z, TYLER D S, et al. Utilizing quantitative polymerase chain reaction to evaluate prostate stem cell antigen as a tumor marker in pancreatic cancer[J]. Ann Surg Oncol, 2006,13(12): 1645-1654. DOI:  10.1245/s1043400690295.
[10]WU X, YE Y, KIEMENEY L A, et al. Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer[J]. Nat Genet, 2009, 41(9): 991-995. DOI:  10.1038/ng.421.
[11]WANG S, TANG J, WANG M, et al. Genetic variation in PSCA and bladder cancer susceptibility in a Chinese population[J]. Carcinogenesis, 2010, 31(4): 621-624. DOI: 10.1093/carcin/bgp323.
[12]MARRA E, UVA P, VITI V, et al. Growth delay of human bladder cancer cells by prostate stem cell antigen downregulation is associated with activation of immune signaling pathways[J]. BMC Cancer, 2010, 10:129.DOI: 10.1186/1471240710129.
[13]DANNULL J, DIENER P A, PRIKLER L, et al. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer[J]. Cancer Res, 2000, 60(19): 5522-5528.
[14]MORGENROTH A, CARTELLIERI M, SCHMITZ M, et al. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered Tcells[J]. Prostate, 2007, 67(10): 1121-1131. DOI:  10.1002/pros.20608.
[15]JENA B, DOTTI G, COOPER L J. Redirecting Tcell specificity by introducing a tumorspecific chimeric antigen receptor[J]. Blood, 2010, 116(7): 1035-1044. DOI: 10.1182/blood201001043737.
[16]PORTER D L, LEVINE B L, KALOS M, et al. Chimeric antigen receptormodified T cells in chronic lymphoid leukemia[J]. N Engl J Med, 2011, 365(8): 725-733. DOI: 10.1056/NEJMoa1103849.
[17]GARFALL A L, MAUS M V, HWANG W T, et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma[J]. N Engl J Med, 2015,373: 1040-1047. DOI: 10.1056/NEJMoa1504542.
[18]TASIAN S K, KENDERIAN S S, SHEN F, et al. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia[J]. Blood, 2017,129(17): 2395-2407. DOI: 10.1182/blood201608736041.
[19]ORMH J M, BEDOYA F, FRIGAULT M J, et al. CARs in the lead against multiple myeloma[J]. Curr Hematol Malig Rep, 2017, 12(2): 119-125. DOI:  10.1007/s1189901703732.
[20]SAFFRAN D C, RAITANO A B, HUBERT R S, et al. AntiPSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts[J]. Proc Natl Acad Sci U S A, 2001, 98(5): 2658-2663. DOI:  10.1073/pnas.051624698.
[21]WEI X, LAI Y, LI J, et al. PSCA and MUC1 in nonsmallcell lung cancer as targets of chimeric antigen receptor T cells[J]. Oncoimmunology, 2017, 6(3): e1284722. DOI: 10.1080/2162402X.2017.1284722. 

更新日期/Last Update: 2018-07-02